Navigation Links
Jeanne Baret, botanist and first female circumnavigator, finally commemorated in name of new species
Date:1/3/2012

n he heard an NPR interview with Baret's biographer, Glynis Ridley, author of The Discovery of Jeanne Baret (Crown, 2010).

S. baretiae is a vine endemic to the Amotape-Huancabamba zone of southern Ecuador and northern Peru and grows in the understory of montane forests and disturbed roadside and pasture vegetation. Its flower petals have been seen in shades of violet, yellow, or white. The leaves of S. baretiae are highly variable in shape, as are the leaves of the species that Commerson originally intended to name after Baret. Then, as now, this seems a fitting tribute to a botanist uniting seemingly contradictory qualities: a woman dressed as a man, a female botanist in a male-dominated field, and a working class woman who travelled farther than most aristocrats of her time.


'/>"/>

Contact: Glynis Ridley
Glynis.ridley@gmail.com
502-681-2275
Pensoft Publishers
Source:Eurekalert  

Page: 1 2

Related biology news :

1. A Spanish botanist searches for prehistoric flora refuges in China
2. Amateur botanists discover a genuflecting plant in Brazil
3. Amateur botanists in Brazil discover a genuflexing plant
4. Fellowship to UC Riverside botanist encourages Hispanic students to take up research
5. Rare Pennsylvania fungus is named for Philadelphia botanist
6. UC Riverside botanist to receive Paul Ecke Jr. Award of Excellence
7. UC Riverside botanist receives Botanical Society of Americas highest honor
8. Severe congenital disorder successfully treated in a mouse model for the first time
9. NIST releases first certified reference material for single-wall carbon nanotubes
10. Head-first diversity shown to drive vertebrate evolution
11. First aid after tick bites
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Jeanne Baret, botanist and first female circumnavigator, finally commemorated in name of new species
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Los Angeles, London, New Delhi, Singapore and Washington DC ... to be advertised directly to the patient, and the results ... as the future adoption of pharmacogenetic/genomic testing, according to a ... to be published in the August 2009 issue of the ...
... - In the July issue of Biomaterials , ... Florida (UCF) report on the first lab-grown motor nerves ... in the human body. The model system will ... such as diabetic neuropathy and later, possibly multiple sclerosis ...
... (BOSTON) July 21, 2009 - A menace to ... the World Organisation for Animal Health (OIE) has declared ... cattle-killing disease that threatened its food supply and its ... July 25, 2009. A team from Tufts University,s ...
Cached Biology News:Genetic tests advertised directly to the consumer 2Researchers design first model motor nerve system that's insulated and organized like the human body 2Ethiopian government celebrates rinderpest eradication 2Ethiopian government celebrates rinderpest eradication 3
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. (NASDAQ: ... is striving to become a leader in the development ... announced that the final CVac data from the Phase ... clear trend for a clinically meaningful improvement in Overall ... remission patients. In the group of second ...
(Date:5/21/2015)... 2015  The EveryLife Foundation for Rare Diseases ... Amy Klobuchar (D-MN) today for introducing ... Treatments, or OPEN ACT. Supported by ... this bipartisan legislation promises to rapidly bring hundreds ... disease patients by incentivizing drug makers to "repurpose" ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... $2.0 Million -, MONTVALE, N.J., Aug. 26 ... it has secured,$2.0 million through the sale of approximately ... under its June 2007 equity financing agreement,with an investment ... Pharmaceuticals exercised its option to complete the third,and final ...
... to empower purification of stem ... cells and their differentiated progeny, ... and the Burnham Institute for Medical Research,("Burnham") today announced ... applications on Cyntellect,s in situ live cell imaging and,laser ...
... The 2008 European Gene,Expression Targeting Platform ... Biogenics Ltd. for developing the Vascular Targeting,System ... advancements,in gene expression-based treatments where angiogenesis is ... a potent and flexible technology permitting,the limitation ...
Cached Biology Technology:Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 2Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 3Cyntellect to Collaborate With the Burnham Institute for Medical Research 2Cyntellect to Collaborate With the Burnham Institute for Medical Research 3Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 2Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 3